Cancer Clinical Trial Participation Amongst Culturally and Linguistically Diverse Patients in Australia

IF 1.4 4区医学 Q4 ONCOLOGY Asia-Pacific journal of clinical oncology Pub Date : 2024-11-09 DOI:10.1111/ajco.14133

Jaidyn Muhandiramge, Oliver J. Nilsen, Umbreen Hafeez

{"title":"Cancer Clinical Trial Participation Amongst Culturally and Linguistically Diverse Patients in Australia","authors":"Jaidyn Muhandiramge, Oliver J. Nilsen, Umbreen Hafeez","doi":"10.1111/ajco.14133","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>Clinical trials play a large role in oncological. Many barriers to participation in cancer clinical trials exist, including a patient's status as “culturally and linguistically diverse (CALD)”. Globally, it is thought that CALD patients experience lower rates of trial participation, although very few studies quantify rates of cancer clinical trial participation in this group. Our study therefore aims to characterize CALD participation in cancer clinical trials in an Australian setting.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a retrospective analysis of data from the Cancer Clinical Trials Centre at Austin Health, a large tertiary metropolitan cancer center in Melbourne, Australia. Participation in cancer clinical trials between groups was compared using simple descriptive analysis, Chi-squared analysis, and logistic regression.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 2568 patients (mean age 57.9 years, 37% female) offered entry into a cancer clinical trial between 2018 and 2023, 26% were from a CALD background (<i>n</i> = 678), and 9% had a preferred language other than English (<i>n</i> = 219). A greater proportion of non-CALD patients participated in a cancer clinical trial compared with CALD patients (37% versus 33% respectively, <i>p</i> = 0.04). In logistic regression models, Arabic (OR, 0.46; 95% CI, 0.21–0.93 [univariate]) and Greek (OR, 0.54; 95% CI, 0.31–0.91 [multivariate]) language groups, along with overall CALD status (OR, 0.81; 95% CI, 0.67–0.99 [univariate]) were associated with lower cancer clinical trial participation.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>We found that CALD patients, those born in non-English speaking countries, and specific language groups, were associated with lower cancer clinical trial participation.</p>\n </section>\n </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"21 1","pages":"58-64"},"PeriodicalIF":1.4000,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asia-Pacific journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajco.14133","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Clinical trials play a large role in oncological. Many barriers to participation in cancer clinical trials exist, including a patient's status as “culturally and linguistically diverse (CALD)”. Globally, it is thought that CALD patients experience lower rates of trial participation, although very few studies quantify rates of cancer clinical trial participation in this group. Our study therefore aims to characterize CALD participation in cancer clinical trials in an Australian setting.

Methods

We conducted a retrospective analysis of data from the Cancer Clinical Trials Centre at Austin Health, a large tertiary metropolitan cancer center in Melbourne, Australia. Participation in cancer clinical trials between groups was compared using simple descriptive analysis, Chi-squared analysis, and logistic regression.

Results

Of 2568 patients (mean age 57.9 years, 37% female) offered entry into a cancer clinical trial between 2018 and 2023, 26% were from a CALD background (n = 678), and 9% had a preferred language other than English (n = 219). A greater proportion of non-CALD patients participated in a cancer clinical trial compared with CALD patients (37% versus 33% respectively, p = 0.04). In logistic regression models, Arabic (OR, 0.46; 95% CI, 0.21–0.93 [univariate]) and Greek (OR, 0.54; 95% CI, 0.31–0.91 [multivariate]) language groups, along with overall CALD status (OR, 0.81; 95% CI, 0.67–0.99 [univariate]) were associated with lower cancer clinical trial participation.

Conclusion

We found that CALD patients, those born in non-English speaking countries, and specific language groups, were associated with lower cancer clinical trial participation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

澳大利亚不同文化和语言患者参与癌症临床试验的情况。

目的：临床试验在肿瘤治疗中发挥着重要作用。参与癌症临床试验存在许多障碍，其中包括患者的 "文化和语言多样性（CALD）"身份。在全球范围内，人们认为 CALD 患者的试验参与率较低，但很少有研究对这一群体的癌症临床试验参与率进行量化。因此，我们的研究旨在了解 CALD 参与澳大利亚癌症临床试验的情况：我们对澳大利亚墨尔本奥斯汀健康中心（Austin Health）癌症临床试验中心的数据进行了回顾性分析。采用简单描述性分析、Chi-squared 分析和逻辑回归对不同组别参与癌症临床试验的情况进行了比较：在2018年至2023年期间，有2568名患者（平均年龄57.9岁，37%为女性）获准参加癌症临床试验，其中26%的患者有CALD背景（n=678），9%的患者首选语言为英语以外的语言（n=219）。与 CALD 患者相比，非 CALD 患者参与癌症临床试验的比例更高（分别为 37% 和 33%，p = 0.04）。在逻辑回归模型中，阿拉伯语组（OR，0.46；95% CI，0.21-0.93 [单变量]）和希腊语组（OR，0.54；95% CI，0.31-0.91 [多变量]）以及总体 CALD 状态（OR，0.81；95% CI，0.67-0.99 [单变量]）与较低的癌症临床试验参与率相关：我们发现，CALD 患者、出生在非英语国家的患者以及特定语言群体与癌症临床试验参与率较低有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Asia-Pacific journal of clinical oncology 医学-肿瘤学

CiteScore

3.40

自引率

0.00%

发文量

175

审稿时长

6-12 weeks

期刊介绍： Asia–Pacific Journal of Clinical Oncology is a multidisciplinary journal of oncology that aims to be a forum for facilitating collaboration and exchanging information on what is happening in different countries of the Asia–Pacific region in relation to cancer treatment and care. The Journal is ideally positioned to receive publications that deal with diversity in cancer behavior, management and outcome related to ethnic, cultural, economic and other differences between populations. In addition to original articles, the Journal publishes reviews, editorials, letters to the Editor and short communications. Case reports are generally not considered for publication, only exceptional papers in which Editors find extraordinary oncological value may be considered for review. The Journal encourages clinical studies, particularly prospectively designed clinical trials.